l-carnitine and fatty liver disease Frontiers L-carnitine supplementation in non-alcoholic fatty
Description
:
BPH is benign and not cancerous
-Synuclein suppresses both the initiation and amplification steps of -synuclein aggregation via competitive binding to surfaces
Calcium targeting therapies Another potential target for neuroprotection in PD is plasma membrane CAV-1 L-type calcium channel (Ilijic et al
Keenan RT, Botson JK, Masri KR, Padnick-Silver L, Lamoreaux B, Albert JA, et al
